Reuters · Oct 2025
Reuters reported that Algen agreed to license its AI-driven gene-editing platform to AstraZeneca in a deal worth up to $555 million for immune system-related therapies.
Using CRISPR to find treatments for cancer and inflammation
Company research
Public company, workplace, funding, and market signals
Overview
Algen Biotechnologies is a San Francisco-based biotech platform company founded as a UC Berkeley spin-out that uses proprietary CRISPR gene modulation and AI foundation models to reverse-engineer disease trajectories, decode gene/RNA signaling, and identify therapeutic targets for hard-to-treat diseases, especially oncology and immunology/inflammation.
Primary product
AlgenBrain platform, powered by the AlgenCRISPR gene-modulation system
Founded
2018
Headquarters
San Francisco, California, United States
Team size
10-20
Industry
Biotechnology Research
Sub-industry
AI-powered CRISPR functional genomics drug discovery
Offices
665 3rd St #280, San Francisco, CA 94107, United States (HQ)
Open Positions
0 jobs at Algen Biotechnologies
No open positions
Check back later for new openings